

## PRESS RELEASE

### **LEON Closes Oversubscribed Financing to Drive Global LNP Manufacturing Scale-Up**

**Munich, Planegg (Germany), February 12<sup>th</sup>, 2026** – leon-nanodrugs GmbH (LEON) today announced the successful closing of a financing round, with participation from both existing and new investors. The round was significantly oversubscribed, underscoring strong investor conviction in LEON’s proprietary technology, commercial readiness, and accelerating global demand for scalable nanoparticle manufacturing solutions.

The proceeds will support the market launch of LEON’s NANO® systems, marking the company’s transition from advanced development into full commercial deployment. The financing will also fuel expansion of commercial activities to meet rising demand for scalable nanoparticle manufacturing technologies from pharmaceutical and biotechnology companies worldwide.

LEON’s platform addresses a critical bottleneck in advanced therapeutics manufacturing. RNA-based medicines, cancer vaccines, cell and gene therapies, and personalized treatments increasingly require highly reproducible nanoparticle production across small-batch, rapid-turnaround, and GMP-scale settings. LEON’s systems are engineered to meet these demands while enabling seamless translation from early development through commercial manufacturing.

At the core of the platform is LEON’s proprietary FR-JET® mixing technology, which overcomes key limitations of conventional nanoparticle manufacturing approaches. FR-JET® enables robust scale-up without process redesign, reducing operational risk, ensuring consistent product quality, and accelerating time-to-market for advanced therapeutic programs.

“We are grateful for the strong confidence our investors continue to place in LEON,” said Christian Nafe, CFO of LEON. “The financing gives us the momentum to scale our commercial footprint, support our partners globally, and continue advancing a manufacturing platform designed for the next generation of therapeutics.”

“LEON has reached an important inflection point,” said Dr. Frank Mühlenbeck, Managing Partner at LBBW Venture Capital and Chairman of LEON’s Supervisory Board. “With market-ready systems, a differentiated technology base, and growing customer demand, we believe LEON is well positioned to emerge as a leader in scalable nanoparticle manufacturing.”

#### **ABOUT LEON (leon-nanodrugs GmbH)**

Based in Planegg/Munich, LEON specializes in the development and commercialization of scalable nanoparticle manufacturing technologies from discovery to GMP. Powered by its patented FR-JET® mixing technology, LEON enables formulation-adaptive processes that reduce scale-up risk and ensure consistent product quality across development and commercial manufacturing.

For further information, please visit <https://leon-nanodrugs.com/> and follow us on [LinkedIn](#).

**CONTACT:**

**leon-nanodrugs GmbH**

Maja Kuhar, Director Marketing & Investor Relations

Phone: +49-89-41424889-98

Mail: [m.kuhar@leon-nanodrugs.com](mailto:m.kuhar@leon-nanodrugs.com)